Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Cancer ; 3(10): 1260-1270, 2022 10.
Article in English | MEDLINE | ID: mdl-35941262

ABSTRACT

Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and transcriptomic heterogeneity. Subtypes based upon predominant transcription factor expression have been defined that, in mouse models and cell lines, exhibit potential differential therapeutic vulnerabilities, with epigenetically distinct SCLC subtypes also described. The clinical relevance of these subtypes is unclear, due in part to challenges in obtaining tumor biopsies for reliable profiling. Here we describe a robust workflow for genome-wide DNA methylation profiling applied to both patient-derived models and to patients' circulating cell-free DNA (cfDNA). Tumor-specific methylation patterns were readily detected in cfDNA samples from patients with SCLC and were correlated with survival outcomes. cfDNA methylation also discriminated between the transcription factor SCLC subtypes, a precedent for a liquid biopsy cfDNA-methylation approach to molecularly subtype SCLC. Our data reveal the potential clinical utility of cfDNA methylation profiling as a universally applicable liquid biopsy approach for the sensitive detection, monitoring and molecular subtyping of patients with SCLC.


Subject(s)
Cell-Free Nucleic Acids , Lung Neoplasms , Small Cell Lung Carcinoma , Animals , Mice , Cell-Free Nucleic Acids/genetics , Small Cell Lung Carcinoma/diagnosis , Epigenome/genetics , DNA Methylation/genetics , Lung Neoplasms/diagnosis , Transcription Factors/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...